1. Scrip
  2. >>Market Snapshot

Lupus Market Snapshot: There's No Debate It's A Blockbuster Opportunity

 
• By Jessica Merrill

Several drug makers are working to bring the next treatment for lupus to market, and the level of interest across the industry suggests the therapeutic area represents a big commercial opportunity.

Medecine concept - Blackboard with text "Lupus", book, pills and stethoscope on blue wooden background

Lupus is a category that has experienced lots of setbacks and disappointments, but the tide appears closer to turning than ever before given the large number of promising drugs for lupus advancing through the pipeline.

Scientific advancements and better understanding of the disease are helping to fuel the investment, but lupus also remains an autoimmune disease with few treatment options at a time when other autoimmune diseases like

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Snapshot

IgAN Market Snapshot: Growing Market, But Patient Segmentation Still A Question

 
• By Alaric DeArment

IgA nephropathy has gone from having zero to three approved treatments in just a few years, with over half a dozen more in late-stage development. But there are still many unknowns.

Atopic Dermatitis Market Snapshot: A Crowded Field With Room To Grow

 
• By Jessica Merrill

Topical, oral and biologic drugs have made a difference for patients with atopic dermatitis, but full control remains elusive for many, with the heterogeneous condition, leaving open a door for new medications.

Myeloma Market Snapshot: New Drug Classes On The Way, But Cost Could Be A Problem

 
• By Alaric DeArment

More BCMA-directed therapies are in development, as well as ones targeting GPRC5D and FcRH5, along with CELMoDs. The question is how to bring those into therapy and pay for them.

Myeloma Market Snapshot: Backlogs Dog BCMA CAR-Ts As Treatment Paradigm Evolves

 
• By Alaric DeArment

KOLs told Scrip about how they are incorporating new immunotherapies into treatment and combining existing agents, but some new drug classes have struggled to take root.

More from Scrip

Copycats Compound Novo’s Wegovy Growth Problems

 
• By Andrew McConaghie

The US FDA has ordered compounders of the Danish firm's obesity drug semaglutide to shut up shop later this month, but competition from Eli Lilly is only increasing.

Stock Watch: Market Optimism Outshines Q1 Currency And Tariff Woes

 
• By Andy Smith

The weak US dollar helped some companies reporting first-quarter results and hindered others reporting in stronger currencies. But even the impacts of currencies and Medicare modernization on first-quarter revenues were overlooked when an end to the trade wars seemed possible.

First Win For AstraZeneca’s Enhertu In Early-Stage Breast Cancer Treatment

 
• By Andrew McConaghie

Already dominating in later lines of breast cancer treatment, Enhertu could now displace both chemotherapy combinations and Roche’s Kadcyla in early-stage HER2-positive patients.